18.98
price up icon0.58%   0.11
after-market アフターアワーズ: 18.89 -0.09 -0.47%
loading

Sarepta Therapeutics Inc (SRPT) 最新ニュース

pulisher
Jun 18, 2025

Sarepta Therapeutics’ SWOT analysis: gene therapy leader faces safety hurdles - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta - Bluefield Daily Telegraph

Jun 18, 2025
pulisher
Jun 18, 2025

Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Sarepta Therapeutics (SRPT): Mizuho Lowers Price Target to $40 | SRPT Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Roku upgraded, Sarepta downgraded: Wall Street’s top analyst calls - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Sarepta (SRPT) Faces Price Target Cut Amid Liver Failure Concerns | SRPT Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

TD Cowen downgrades Sarepta Therapeutics to 'hold' - TradingView

Jun 18, 2025
pulisher
Jun 18, 2025

Sarepta stock plunges 42% after second fatal liver failure case - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Another Gene Therapy Death; Biopharma M&A Picks Up; a Vaccine Board of Vaccine Skeptics - BioSpace

Jun 18, 2025
pulisher
Jun 18, 2025

Sarepta (SRPT) Downgraded to Hold with Revised Price Target | SRPT Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Analysts recommendations: Sarepta Therapeutics, Broadcom, Enphase Energy, Lam Research… - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Sarepta stock downgraded by TD Cowen on Elevidys approval concerns - Investing.com

Jun 18, 2025
pulisher
Jun 17, 2025

Sarepta: TD Cowen downgrades rating, cuts PT on FDA pullback risk for Elevidys - Investing.com

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Therapeutics (SRPT) Price Target Lowered by Deutsche Ban - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Therapeutics: Overcoming Challenges and Capturing Growth Opportunities Amid Elevidys Setback - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc.SRPT - PR Newswire

Jun 17, 2025
pulisher
Jun 17, 2025

Second Patient Dies Following Treatment With Sarepta’s DMD Gene Therapy Elevidys - CGTLive®

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Therapeutics price target lowered to $28 on safety concerns - Investing.com

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Therapeutics price target lowered to $28 on safety concerns By Investing.com - Investing.com UK

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Therapeutics (SRPT) PT Lowered to $28 at Evercore ISI - StreetInsider

Jun 17, 2025
pulisher
Jun 17, 2025

SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm | FinancialContent - FinancialContent

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Therapeutics (NasdaqGS:SRPT) SRP-9003 Gene Therapy Earns FDA Platform Technology Designation - simplywall.st

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Therapeutics (SRPT) Downgraded by Goldman Sachs to Neutral | SRPT Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Therapeutics (SRPT) Downgraded by Morgan Stanley | SRPT Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Therapeutics (SRPT) Target Price Slashed by Baird | SRPT Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

From $172 to $20: Sarepta’s Spectacular Fall - Trefis

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Reports Second Death of Patient Using Its Gene Therapy - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Therapeutics’ SWOT analysis: gene therapy pioneer faces safety hurdles By Investing.com - Investing.com South Africa

Jun 17, 2025
pulisher
Jun 17, 2025

Lilly adds highest Zepbound doses to DTC offering - statnews.com

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Therapeutics (SRPT) Target Price Slashed by Barclays | S - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Therapeutics (SRPT) Target Price Slashed by Barclays | SRPT Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Pharmalittle: We're reading about a Lilly deal, a gene therapy shock for Duchenne families, and more - statnews.com

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Therapeutics’ SWOT analysis: gene therapy pioneer faces safety hurdles - Investing.com India

Jun 17, 2025
pulisher
Jun 17, 2025

SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. is being Investigated for Securities Fraud after Second Elevidys Death; Investors with Losses are Notified to Contact BFA Law - Business Wire

Jun 17, 2025
pulisher
Jun 17, 2025

SRPT Stock: What’s Happening With Sarepta Therapeutics? - Forbes

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Therapeutics (SRPT): Analyst Lowers Price Target Amid In - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta (SRPT) Price Target Slashed, Uncertainty Surrounds Future | SRPT Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Wolfe Research Initiates Sarepta (SRPT) with Neutral Outlook Ami - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Wolfe Research Initiates Sarepta (SRPT) with Neutral Outlook Amid Safety Concerns | SRPT Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

This Week’s CGT News: Investigating the Long-Term Safety of Gene Therapy for Hemophilia B - themedicinemaker.com

Jun 17, 2025
pulisher
Jun 17, 2025

2nd death reported in Sarepta gene therapy trial for Duchenne muscular dystrophy - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Biotech pauses trial after second patient death linked to gene therapy - The Washington Post

Jun 17, 2025
pulisher
Jun 17, 2025

Sarepta Therapeutics Stock Plunges as Second Patient Dies Taking Its Drug - MSN

Jun 17, 2025
pulisher
Jun 16, 2025

Sarepta (SRPT) Faces Price Target Cut Amid Gene Therapy Concerns - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm - FinancialContent

Jun 16, 2025
pulisher
Jun 16, 2025

Elevidys’ second liver death hits Sarepta, sends DMD ripples - BioWorld MedTech

Jun 16, 2025
pulisher
Jun 16, 2025

Sarepta Market Dynamics For Elevidys Imperiled By Second Patient Death - insights.citeline.com

Jun 16, 2025
pulisher
Jun 16, 2025

Sarepta shares crash as second patient dies after receiving its gene therapy - MSN

Jun 16, 2025
pulisher
Jun 16, 2025

Health Care Down as Sarepta Slides -- Health Care Roundup - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Second patient death reported with gene therapy for muscular dystrophy - Hazleton Standard Speaker

Jun 16, 2025
pulisher
Jun 16, 2025

Second Teenage Boy Dies From Liver Failure After Sarepta Gene Therapy Treatment - Bloomberg

Jun 16, 2025
pulisher
Jun 16, 2025

Wolfe Research Begins Coverage of Sarepta (SRPT) with Neutral Rating | SRPT Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Sarepta Therapeutics Stock Drops 44.4% Amid Elevidys Gene Therapy ConcernsNews and Statistics - IndexBox

Jun 16, 2025
pulisher
Jun 16, 2025

Sarepta Crashes To Nine-Year Low After A Second Gene Therapy Patient Dies - Investor's Business Daily

Jun 16, 2025
pulisher
Jun 16, 2025

These Stocks Moved the Most Today: Sarepta, AMD, Tesla, U.S. Steel, Roku, Sage Therapeutics, and More - Barron's

Jun 16, 2025
pulisher
Jun 16, 2025

Sarepta's Shares Plummet After Duchenne Treatment Halt - Finimize

Jun 16, 2025
pulisher
Jun 16, 2025

AMD pops, Sarepta tanks, EchoStar & Trump: Trending Tickers - Yahoo Finance

Jun 16, 2025
pulisher
Jun 16, 2025

Sarepta Therapeutics (SRPT) Sees Target Price Adjustment by Jeff - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Sarepta stock rating cut by Morgan Stanley on patient safety concerns - Investing.com

Jun 16, 2025
pulisher
Jun 16, 2025

After second Sarepta death, Duchenne muscular dystrophy community is racked by recrimination and worry - statnews.com

Jun 16, 2025
$20.74
price up icon 0.29%
$36.14
price up icon 2.09%
$20.92
price up icon 2.60%
$105.90
price up icon 0.46%
$105.09
price up icon 2.02%
biotechnology ONC
$266.80
price up icon 3.61%
大文字化:     |  ボリューム (24 時間):